This review summarizes the outcomes from phase II/III trials with long-term lenalidomide maintenance therapy alone or in combination with other agents in post-ASCT and non-transplant settings for newly diagnosed patients with MM. We review recent data considering a combination with newer medications and ongoing trials. We also review the optimal duration, MRD negativity rate, and safety and tolerability aspects of lenalidomide maintenance therapy. This review aims to present the current and emerging clinical evidence that supports using lenalidomide as a backbone for maintenance therapy in patients with MM.
There is increasing evidence to support lenalidomide as the backbone of combination therapy in the maintenance setting.
这篇综述总结了新诊断的MMs患者在ASCT后和非移植环境中单独使用来那度胺长期维持治疗或与其他药物联合使用的II/III期试验的结果。我们回顾了最近的数据,考虑了与新药物和正在进行的试验的组合。我们还回顾了最佳持续时间,MRD阴性率,来那度胺维持治疗的安全性和耐受性方面。这篇综述旨在介绍当前和新兴的临床证据,这些证据支持使用来那度胺作为MM患者维持治疗的骨干。
越来越多的证据支持来那度胺作为维持环境中联合治疗的骨干。